Invivyd (IVVD) FCF Margin (2024 - 2025)
Invivyd (IVVD) reported FCF Margin of 89.82% for Q4 2025, up 18229.0% on a YoY basis from N/an in Q4 2024, and down 42.94% quarter-over-quarter from 62.84% in Q3 2025.
Invivyd (IVVD) FCF Margin (2024 - 2025) Analysis & Trends
Invivyd has reported FCF Margin for 2 years, with the latest figure at 89.82% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 18229.0% year-over-year to 89.82%; the trailing twelve-month figure through Dec 2025 stood at 109.1% (up 56309.0% YoY), and the FY2025 full-year result was 109.1%, up 56309.0% from the prior year.
- FCF Margin for Q4 2025 stood at 89.82%, down from 62.84% in the prior quarter.
- The five-year high for FCF Margin was 62.84% in Q3 2025, with the low at 1837.41% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | -89.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -89.82% |
| Sep 30, 2025 | -62.84% |
| Jun 30, 2025 | -112.95% |
| Mar 31, 2025 | -188.19% |
| Dec 31, 2024 | -272.11% |
| Sep 30, 2024 | -441.65% |
| Jun 30, 2024 | -1,837.41% |